Answers are grounded in this paper and cite their sources.
This direct comparison of large matched cohorts undergoing SEEG and SDE implantation reveals distinctly better procedural morbidity favoring SEEG. These modalities intrinsically evaluate somewhat different populations, with SEEG being more versatile and applicable to a range of scenarios, including nonlesional and bilateral cases, than SDE. The significantly favorable adverse effect profile of SEEG should factor into decision making when patients with pharmacoresistant epilepsy are considered for intracranial evaluations.
No takes yet. Share an insight, caveat, or question.
Tandon et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: